ASX 200 at a record high? Here’s where I still see value

Woman using a pen on a digital stock market chart in an office.

The S&P/ASX 200 Index (ASX: XJO) is hovering around record highs again on Friday.

On the surface, that can make it feel like everything is expensive. The banks are trading near peak valuations. The major miners have rebounded strongly. Some high-quality industrials look fully priced.

But a record index does not mean a fully priced market. It often just means value options have narrowed.

Right now, I think there are still pockets of genuine value on the ASX. You just have to look beyond the obvious.

Here’s where I’m seeing opportunity.

The healthcare sector

One of the clearest areas of value, in my view, is healthcare.

High-quality global businesses have been sold off over the past couple of years due to earnings resets, temporary headwinds, or sentiment shifts. But structurally, their long-term growth drivers remain intact.

Take CSL Ltd (ASX: CSL).

It has not been a smooth ride for shareholders recently. But plasma collection volumes have improved, margins are on the path to recovery, and the company continues to invest in its pipeline. The share price de-rating means the risk-reward profile looks far more attractive than it did at the peak.

I also think Cochlear Ltd (ASX: COH) fits into this bucket. Hearing loss is a major problem globally, and Cochlear’s world-class products give it a powerful competitive advantage. Structural demand, global exposure, and strong cash generation at a reasonable multiple? That’s the kind of value I look for at record market highs.

The tech sector

Another area I still see value is among tech stocks that have been punished in 2026.

The index may be at record highs, but plenty of former high-flyers are still well below their peaks.

For example, WiseTech Global Ltd (ASX: WTC) has endured a significant pullback due to company-specific issues and slowing growth in its core business. However, the long-term opportunity in global logistics software remains large. If earnings reaccelerate over the next couple of years, today’s valuation could look conservative.

Similarly, Xero Ltd (ASX: XRO) continues to build scale globally. It’s no longer priced for perfection like it once was. For a business with strong recurring revenue, global expansion potential, and improving margins, I think it still offers compelling long-term value relative to its quality.

Infrastructure and defensive earnings

If the ASX 200 is expensive, I also want resilience.

Infrastructure-style assets with predictable cash flows can still make sense, even when the index is elevated.

Transurban Group (ASX: TCL) is one example. It owns long-life toll road assets across Australia and North America, many with inflation-linked pricing mechanisms. That provides a built-in buffer against rising costs and economic uncertainty.

When I can buy defensive, cash-generating assets that have visible revenue streams, I am less worried about the broader index level.

Foolish Takeaway

A record high ASX 200 Index doesn’t mean it’s time to panic. It just means you need to be selective.

I’m less interested in chasing crowded trades at premium valuations. Instead, I’m focusing on high-quality healthcare names that have already de-rated, structural growth businesses trading below prior peaks, and defensive infrastructure assets with predictable cash flow.

Value still exists. It just isn’t necessarily where the headlines are pointing.

The post ASX 200 at a record high? Here’s where I still see value appeared first on The Motley Fool Australia.

Should you invest $1,000 in Cochlear Limited right now?

Before you buy Cochlear Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear Limited wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

* Returns as of 20 Feb 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor Grace Alvino has positions in CSL and Transurban Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, Transurban Group, WiseTech Global, and Xero. The Motley Fool Australia has positions in and has recommended Transurban Group, WiseTech Global, and Xero. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.